Palladio Biosciences, Inc., a Centessa company Employee Directory
BiotechnologyPennsylvania, United States11-50 Employees
Palladio Biosciences, Inc. operates in the biotechnology research space as a clinical-stage company focused on kidney-related orphan diseases. Its lead product, lixivaptan, is in Phase 3 clinical development for autosomal polycystic kidney disease (ADPKD), a chronic, progressive condition characterized by fluid-filled cysts in the kidneys and significant burden on patients and families. The company aims to provide a safe, chronic-treatment option that could slow the progression of PKD, addressing an area with no current cure. Based in Horsham, Pennsylvania, Palladio is part of a broader ecosystem of biopharmaceutical firms developing treatments for niche kidney diseases and operates under the umbrella of Centessa. The organization has positioned itself as a clinical-stage company targeting orphan kidney diseases, with a focus on translating its research into therapeutic candidates for patients in need.